After Pfizer/Biontech, the pharmaceutical company Moderna also asked the US Food and Drug Administration (FDA) on Tuesday for urgent approval for a booster vaccine against the omicron variant of the corona virus. In particular, the vaccine is intended to provide protection against variants BA.4 and BA.5.
The UK was the first country to approve the Moderna vaccine in mid-month, which is effective against both the mother coronavirus and the ommicron variant. The British health authority MHRA has announced that the vaccine from the American manufacturer can be used as a booster for adults. The decision was based on clinical trials that had shown a “strong immune response,” it said.
The Moderna vaccine, called Spikevax bivalent Original/Omicron, targets both the original strain of the coronavirus, which first appeared in 2020, and the Omicron variant BA.1. “Good” results were also obtained for the subtypes BA.4 and BA.5 of the omicron variant.
In the EU, Omicron vaccines from both Moderna and Biontech/Pfizer are still being tested. The European Medicines Agency EMA has announced a special meeting on Tuesday 1 September. Then applications for approval of booster vaccinations against the ommicron variant of the virus SARS-CoV-2 should be discussed.
Source: Krone
I’m Wayne Wickman, a professional journalist and author for Today Times Live. My specialty is covering global news and current events, offering readers a unique perspective on the world’s most pressing issues. I’m passionate about storytelling and helping people stay informed on the goings-on of our planet.
